Results 61 to 70 of about 1,036,661 (382)
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine+10 more
wiley +1 more source
Sometimes the Silence Can Be like the Thunder: Access to Pharmaceutical Data at the FDA [PDF]
Those committed to the free exchange of scientific information have long complained about various restrictions on access to the FDA\u27s pharmaceutical data and the resultant restrictions on open discourse.
Ankelhed, Daniel+2 more
core +2 more sources
ASSESSMENT OF MOUSE EMBRYO VIABILITY BY ESTERASIC ACTIVITY DETECTION
In order to evaluate the esterasic activity within the viable embryos we used the Fluorescein diacetate (FDA) staining test. For staining was used a 0.5 mg/ml FDA stock solution. The embryos were recovered at 48 hours post coitus from superovulated Swiss
ALEXANDRA BOLEMAN+3 more
doaj
Analysing musical performance through functional data analysis: rhythmic structure in Schumann's Träumerei [PDF]
Functional data analysis (FDA) is a relatively new branch of statistics devoted to describing and modelling data that are complete functions. Many relevant aspects of musical performance and perception can be understood and quantified as dynamic ...
Almansa, J+1 more
core +2 more sources
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
A review of hospital based ventilator malfunctions reported to the FDA in 2021
Ventilator care is synonymous with Intensive care. These devices are electromechanical and as such can fail. Most failures are without patient incident, injury, and harm.
Stephen Tunnell
doaj +1 more source
Seeking out non-public information : sell-side analysts and the freedom of information act [PDF]
A number of sell-side healthcare analysts gain access to information outside the purview of management through Freedom of Information Act requests to the Food and Drug Administration for records on factory inspections, complaints, and drug and medical ...
Klein, April, Li, Tao, Zhang, Bobo
core +1 more source
Suppression of Mainbeam Deceptive Jammer With FDA-MIMO Radar
Suppression of radar-to-radar jammers, especially the mainbeam jammers, has been an urgent demand in vehicular sensing systems with the expected increased number of vehicles equipped with radar systems.
Lan Lan+5 more
semanticscholar +1 more source
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source